Ephedra (Ma huang)Banned Substance

• The FDA published its final rule on February 11, 2004, effective April 12, 2004 [1].
  
  It declared dietary supplements containing ephedrine alkaloids adulterated under the Federal Food, Drug, and Cosmetic Act — an unreasonable risk under ordinary conditions of use [1]. ^[1]

• This was the first dietary supplement the FDA had ever banned under DSHEA, the 1994 law that otherwise presumes supplements safe until the agency shows harm [2][3]. ^[3]

• By the time of the ban, the FDA and outside reviewers had accumulated more than 16,000 adverse event reports tied to ephedra products [2].
  
  Roughly 155 deaths had been attributed to ephedra-containing stimulant products — attributed, not all causally confirmed [2]. ^[2]

• The 2003 heat-stroke death of Baltimore Orioles pitcher Steve Bechler, while he was using an ephedra supplement, is credited with accelerating the political pressure [2].
  
  The decision itself rested on the pharmacology of ephedrine alkaloids, the peer-reviewed literature and that adverse-event record [1]. ^[2]

• The core hazard is cardiovascular. A 2000 New England Journal of Medicine review of 140 adverse event reports found 47% of the related or possibly related events were cardiovascular [7].
  
  Hypertension was the single most common effect, followed by palpitations and tachycardia, then stroke and seizures [7]. ^[7]

• Central nervous system events made up another 18% of those cases [7].
  
  Ten of the 140 reviewed reports ended in death and 13 in permanent impairment — together 26% of the definite, probable or possible cases [7]. ^[7]

• Dose was not the whole story. Nine serious events occurred in people taking just 12–36 mg/day, with no major medical risk factors [7]. ^[7]

• RAND's HHS-commissioned review pooled 52 clinical trials and over 18,000 manufacturer-submitted adverse event reports [8].
  
  It found a two- to three-fold increase in nausea, vomiting, jitteriness and palpitations versus placebo [8]. About half of its sentinel and possible-sentinel events occurred in apparently healthy people under 30 [8]. ^[8]

• ⚠ RAND is explicit that this is a probable link rather than a statistically established one, since spontaneous adverse-event reporting cannot establish causation by itself [8][9]. ^[8]

• ⚠ A second disagreement sits inside the FDA's own record. Morgenstern and colleagues (2003) found ephedra use was not associated with increased hemorrhagic stroke risk overall, except possibly at higher doses [5]. ^[5]

• Bent and colleagues, cited by the FDA and the Tenth Circuit, found ephedra-alkaloid supplements accounted for 64% of all adverse reactions reported for herbal products in the US [5].
  
  Those products made up 0.82% of herbal product sales [5]. ^[5]

• Beyond the heart and brain, documented serious effects include liver damage and seizures [12].
  
  Psychiatric events — mania, depression, psychosis — have also been reported, sometimes after only two to three times a person's usual amount [17]. ^[12]

• 1994 — DSHEA classifies dietary supplements, ephedra included, as presumptively safe unless the FDA shows an unreasonable risk [6]. ^[6]

• 1995–1997 — adverse-event reports accumulate. In June 1997 the FDA proposes labelling limits, a ban on combining ephedra with other stimulants, and a 7-day duration cap [6]. ^[6]

• April 2000 — the FDA withdraws the proposed numeric dosage and duration limits, after a GAO report finds its data did not adequately support those specific figures [6].
  
  The proposed restrictions on stimulant combinations and warning labels stay in place [6]. ^[6]

• February 2003 — RAND's independent review, commissioned by HHS, concludes ephedra and ephedrine are probably linked to catastrophic events [8].
  
  Steve Bechler dies the same month, and political pressure intensifies [2]. ^[8]

• December 2003 — the FDA announces its intent to ban ephedra-containing supplements [6].
  
  February 11, 2004 — the final rule publishes at 69 Federal Register 6788, closing roughly seven years of review [1]. ^[6]

• That administrative record ran past 130,000 pages, about 19,000 adverse event reports and over 48,000 public comments [5].
  
  The rule took effect on April 12, 2004 [1]. ^[5]

• April 2005 — a Utah federal district court rules the FDA had not shown that products with 10 mg or less of ephedrine alkaloids per daily dose pose an unreasonable risk [5].
  
  It blocks enforcement at or below that threshold [5]. ^[5]

• August 17, 2006 — the Tenth Circuit overturns that ruling in Nutraceutical Corp versus Von Eschenbach [5].
  
  It holds the FDA met its burden, and that no dosage level counts as an acceptable risk, restoring the total ban [5][6]. ^[5]

• July 2008 — the DEA finalizes separate controls on raw ephedrine and pseudoephedrine chemical mixtures [1].
  
  That action targets precursor chemicals, not finished dietary supplements [1]. ^[1]

• Afterwards — a New England Journal of Medicine research letter reports a reduction in ephedra poisonings following the FDA ban [10].
  
  That is the closest thing here to an outcome measure for the rule itself [10]. ^[10]

There is no safe amount to report, and nothing below is guidance. The FDA's pharmacokinetic analysis concluded ephedrine produces cardiovascular effects comparable to a similar dose of epinephrine [5].

The Tenth Circuit leaned on that finding to uphold a total ban rather than a dose-based one [5].

Documented harm at low intakes: nine serious cardiovascular or neurological events in one FDA case review occurred at 12–36 mg/day [7].

Animal and forensic figures span a wide range. The mouse LD50 for ephedra alkaloids is 610 mg/kg, with a probable human lethal dose estimated near 50 mg/kg of body weight [13].

Forensic toxicology puts the lethal adult dose of ephedrine itself around 2 g, while 400 mg has reportedly been survived without serious toxicity [23].

Postmortem blood ephedrine ran 3.49 to 20.5 mg/L across three reported deaths — yet one person survived a level of 23 mg/L [14].

⚠ Pre-ban labelling never agreed either: the FDA's withdrawn 1997 proposal would have capped labels at 8 mg per 6 hours (24 mg/day), while some pharmacy references listed up to 300 mg/day [16].

Those overlapping ranges are the point. Individual susceptibility varies enough that no number in this literature separates safe from lethal [5][16]. ^[5]

If someone has swallowed an ephedra product, contact Poison Control at 1-800-222-1222 or webpoisoncontrol.org for free, confidential, expert guidance [24].

Call 911 first if the person collapses, has a seizure, has trouble breathing, or cannot be woken [24].

Acute ephedrine poisoning can present with nausea and vomiting, chills, cyanosis, fever, tachycardia, dilated pupils, blurred vision, convulsions and pulmonary edema [15].

Blood pressure often runs high at first and can later fall, with reduced urine output in severe overdose [15]. Coma and respiratory failure sit at the severe end [15].

Documented emergency management includes assisted ventilation, avoiding vasopressors, IV phentolamine for severe hypertension, and diazepam or paraldehyde for convulsions [15].

The FDA's standing consumer advice is to stop using any ephedra-containing product [3]. Adverse events go to MedWatch at 1-800-332-1088, or the FDA Consumer Hotline at 1-800-332-4010 [11].

Import Alert 54-13 lets the FDA and US Customs detain and refuse ephedra shipments at ports of entry, personal imports included [20]. ^[24]